Healthcare Professional Sentiments on the MenACWY Vaccination Schedule in the United States
Washington DC, October 4, 2024-- Ipsos partnered with Sanofi to survey health care professionals’ (including pediatricians, family practice physicians, nurse practitioners, and physician associates) opinions regarding the current adolescent meningococcal vaccination schedule, the perceived importance of this vaccination, and obtain their reactions to the potential removal of the MenACWY dose at age 11-12. Overall, respondents showed clear support for maintaining the MenACWY vaccination at 11-12 years of age, coupled with clear concern about unintended consequences that may arise if the recommendation to vaccinate at age 11-12 is eliminated. Physicians included in this survey were hesitant to show support for a situation that could enable any of those unintended consequences to materialize. Surveyed physicians felt that there would be a risk to their adolescent patients if this recommendation was removed, such as leaving some patients totally unprotected against meningococcal disease considering the challenges currently associated with booster dose compliance.
The results of this research provide an additional piece of information to consider and can be helpful to guide broader discussions regarding public health policy around the prevention of meningococcal disease. Similarly, these survey results can be used to inform the acceptability domain of the ACIP’s evidence-to-recommendations framework.
About the Study
Ipsos fielded a 10-minute, self-administered. online cross-sectional survey among HCPs currently practicing in the United States during the period between March 29 to April 22, 2024. Respondents were recruited from opt-in panels of HCPs across the country. In order, to participate in the survey, all respondents had to be board certified, a licensed family practice physician, pediatrician, or a nurse practitioner/physician associate affiliated with a pediatrician, handling a patient load of at least 50 adolescent patients per month if a pediatrician, or 30 per month if a family practice physician, advising on or administering vaccines, stock MenACWY vaccines in practice, and be located primarily in a community-based practice or private health clinic.
Potential respondents were excluded from participation if they were unwilling to provide informed consent to participate in the study, in practice for less than one year, spent less than 75% of professional time providing direct patient care, not involved in advising or administering vaccines, did not have the meningococcal ACWY vaccine stocked in their practice, located in MN, ME, or VT (due to transparency reporting laws in these states for HCPs), or reported a conflict of interest to survey participation (respondent or member of household employed by the pharmaceutical industry, or affiliated communication/advertising agency on a full-time or consultancy basis). Pediatricians also needed to report at least 15% of their patient population being 11-12 years old, while family medicine physicians needed to report at least 10% of their patient population being 11-12 years old to participate in the survey.
The final sample size of 600 HCPs consisted of 301 Pediatricians, 199 Family Practice Physicians, and 100 Nurse Practitioners or physician associates (NP/PAs) practicing in pediatric or family medicine offices. No post-hoc weights were applied to the data, and the findings reflect the opinion of these respondents only.
For more information on this news release, please contact:
Matthew Heffler
Director, US
Healthcare
+1 973 337-3208
[email protected]
About Ipsos
Ipsos is one of the largest market research and polling companies globally, operating in 90 markets and employing over 18,000 people.
Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. We serve more than 5000 clients across the world with 75 business solutions.
Founded in France in 1975, Ipsos is listed on the Euronext Paris since July 1st, 1999. The company is part of the SBF 120 and the Mid-60 index and is eligible for the Deferred Settlement Service (SRD).
ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP www.ipsos.com
